logo
Heatwave Mounjaro warning issued for millions as temperatures soar

Heatwave Mounjaro warning issued for millions as temperatures soar

Yahoo14 hours ago

As the UK braces itself for a heatwave over the next few weeks, with temperatures expected to reach 32C, patients using weight loss medication such as Mounjaro have been issued essential advice by pharmacists.
It's estimated that around 1.5 million Brits are now taking weight-loss drugs, with numbers increasing each week.
The last year has seen a huge increase in the number of people taking GLP-1 receptor agonists, some prescribed by the NHS and others by private doctors, with common injectibles including semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda).
As the temperatures rise, experts are stressing that users must store weight loss injections in a refrigerator (2-8°C or 36-46°F), especially after starting the course.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/tHs6lyJHc4
— We are Primary Care (@PrimaryCareNHS) June 12, 2025
'Weight loss injections can be adversely affected by hot weather, particularly regarding storage and stability," says James O'Loan, obesity specialist and weight loss injection expert at pharmacists Chemist4U.
"Understanding the storage instructions when using any prescribed medication is vital to keep it in optimal condition.
"Although weight loss injections can be stored at room temperature for up to 30 days (some injections are 42 days, so always check with your prescriber or refer to the patient information leaflet), this is only provided the temperature does not exceed 30°C. During hot weather, and to be on the safe side, it is always best to keep your weight loss injections refrigerated if you're able."
The advice for the UK heatwave is also also worth noting for those heading on holiday or travelling during the warmer weather.
However, if you're flying, remember to pack your injections in your carry-on since the baggage hold on a plane can plummet to below-freezing temperatures.
Finding the right temperature for your pen is important: not too hot or too cold. If you inject after incorrectly storing your pen, it might not be safe for use.
"There are a few important things to consider when checking if your weight loss pen is safe to use," says James.
"Inspect the pen to ensure it is not damaged and the medicine inside is clear, with no particles or cloudiness. The liquid should be colourless or slightly yellow. If you have left your pen unrefrigerated during hot weather and are unsure whether it is still safe to use, always consult your prescriber before injecting.
"Staying hydrated whilst taking weight loss injections is key. Weight loss injections can cause side effects such as nausea, constipation, diarrhoea and dizziness, which, without sufficient fluids, can lead to dehydration.
"We recommend drinking plenty of water throughout the day, even when you're not thirsty. If experiencing diarrhoea or vomiting, try using electrolyte drinks, rehydrate quickly and apply sunscreen whenever you are outdoors. This will help those who suffer from heightened sensitivity to UV rays.'
Yes. Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance.
Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately, it doesn't need to be declared.
Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for.
'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.'
Recommended reading:
When will Mounjaro be rolled out on the NHS?
Mounjaro and Ozempic warning for anyone planning a holiday this summer
Warning as Mounjaro and Ozempic sold without prescription
'Non-disclosure is a gamble that's simply not worth taking," says Niraj.
"If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated.
'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills.
"With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.'
Insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?

Yahoo

time4 hours ago

  • Yahoo

Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II diabetes (T2D) and Wegovy for obesity. Ozempic and Wegovy include the same compound, semaglutide, a GLP-1 receptor agonist. While Ozempic was first approved in 2017, Wegovy was approved later in 2021. Both medications have witnessed rapid demand because of increased prescription rates, which have boosted their sales. Ozempic and Wegovy generated combined sales of DKK 50.1 billion in the first quarter of 2025, accounting for around 66% of the company's total revenues. Novo Nordisk is a global market leader in the diabetes GLP-1 segment, with around 54% value market share as of March-end. The company is also a global obesity market leader with a branded volume market share of 68.7% as of the end of the first quarter of 2025. In the second half of 2024, Novo Nordisk faced supply shortages of Ozempic and Wegovy, leading to their inclusion on the FDA's Drug Shortage list and slowing sales growth. After ramping up manufacturing, the FDA, earlier this year, declared the drugs are no longer in short supply, positioning them for a potential rebound in upcoming quarters. NVO has also struck deals with a pharmacy benefit manager and telehealth providers for marketing Wegovy in the United States, which are likely to give the company a commercial advantage over its competitors in the obesity market. Approvals for new indications can also drive sales of Ozempic and Wegovy higher. Ozempic's label has been expanded to include the treatment of cardiovascular risk reduction as well as for kidney failure in T2D patients. Wegovy's label, on the other hand, has been expanded to reduce the risks of major adverse cardiovascular events. Novo Nordisk is also looking to further expand Wegovy's indication for preventing heart failure in obesity patients. Additionally, a regulatory application seeking the approval of oral semaglutide 25 mg for obesity is currently under review by the FDA. The obesity market is heating up and is expected to expand to $100 billion by 2030, according to data from Goldman Sachs. Novo Nordisk's arch-rival in the obesity market is Eli Lilly LLY. NVO's Ozempic and Wegovy face strong competition from Lilly's tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity). Despite being on the market for less than three years, Lilly's Mounjaro and Zepbound have witnessed strong sales driven by rapid demand. Several companies like Amgen AMGN and Viking Therapeutics VKTX are also making rapid progress in the development of GLP-1-based candidates in their clinical pipeline. Amgen has begun a broad phase III program on its dual GIPR/GLP-1 receptor agonist, MariTide, across obesity, obesity-related conditions and type II diabetes, with the first two phase III studies initiated in March. Viking Therapeutics' dual GIPR/GLP-1 receptor agonist, VK2735, is being developed both as oral and subcutaneous formulations for the treatment of obesity. Phase III studies with the subcutaneous formulation of VK2735 are on track to begin this year. Year to date, Novo Nordisk shares have lost 13.6% against the industry's 2.5% growth. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading above its 50-day moving average, but below its 200-day moving average. Image Source: Zacks Investment Research Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company's shares currently trade at 17.67 forward earnings, which is higher than 15.63 for the industry. However, the stock is trading much below its five-year mean of 29.26. Image Source: Zacks Investment Research Earnings estimates for 2025 have improved from $3.80 to $3.84 per share over the past 60 days. During the same time frame, Novo Nordisk's 2026 earnings per share estimates have improved from $4.60 to $4.64. Image Source: Zacks Investment Research The stock's return on equity on a trailing 12-month basis is 80.95%, which is higher than 33.56% for the large drugmaker industry, as seen in the chart below. Image Source: Zacks Investment Research Novo Nordisk currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

What is rabies, how to avoid it and how to recognise the symptoms?
What is rabies, how to avoid it and how to recognise the symptoms?

Yahoo

time7 hours ago

  • Yahoo

What is rabies, how to avoid it and how to recognise the symptoms?

Rabies is a rare and serious infection that affects the brain and the nervous system, so it is important to be aware of information about it. Human cases of rabies are very rare in the UK, but it poses a risk to travellers visiting regions where the disease remains prevalent. While the risk is still small, rabies is more common in parts of Asia, Africa, Central America and South America. Here's all you need to know about the infection, including how to recognise symptoms and how to avoid it. If you're travelling to a country where rabies is present, it's worth knowing how to reduce your risk - read our blog post for more info. 🔗 — UK Health Security Agency (@UKHSA) June 18, 2025 According to the NHS website, rabies is spread by mammals, such as dogs, bats, raccoons and foxes. You can get rabies if you're bitten or scratched by an infected animal. Additionally, it can be passed on if an infected animal licks your eyes, nose or mouth, or you have a wound that's licked by an infected animal. Rabies symptoms usually take between three to 12 weeks to appear, but they can also occur within a few days or take several months or years. Symptoms of the infection include: numbness or tingling where you were bitten or scratched seeing things that are not there (hallucinations) feeling very anxious or energetic difficulty swallowing or breathing being unable to move (paralysis) Once symptoms develop in an infected person after they have been exposed, it is almost always fatal. The UK Health Security Agency (UKHSA) says you need to take a number of immediate steps if you believe you have been in contact with a rabies-infected animal. You should wash the wound with plenty of soap and water for several minutes to reduce the risk of infection. Additionally, seek local medical attention without delay, as treating it sooner will be more effective. They add: "Contact your GP on return to the UK, even if you received post-exposure treatment abroad or the exposure happened several weeks ago. "You may need to continue a course of rabies vaccines. If you have a record of any treatment given, remember to bring this with you." According to the NHS website, the level of protection varies, but a full course should last one or two years. People who are travelling to areas with a risk of rabies more than a year after their course of vaccines can have a single booster dose. If you're travelling to a region where there is a chance of rabies, you need to take preventative measures. The UKHSA recommends consulting a travel health professional before your trip. Recommended reading: Person dies in Yorkshire from rabies after contact with a stray dog in Morocco How long do colds last and how can you cure them quickly? Urgent Mounjaro and Ozempic warning for anyone planning a holiday They can determine if pre-exposure vaccination is recommended based on your destination and planned activities. The UKHSA adds: "Vaccination is particularly important if you'll be staying for over a month, engaging in outdoor activities, or travelling to areas with limited access to medical care." It is also advised to avoid contact with animals as much as possible when travelling.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store